Xiaoli Wang1,2,3, Xianghua Guo4, Qianqian Xin5, Yang Pan1,2,3, Yaling Hu5, Jing Li5, Yanhui Chu6, Yingmei Feng4, Quanyi Wang1,2,3. 1. Beijing Center for Disease Prevention and Control, Beijing, China. 2. Beijing Research Center for Preventive Medicine, Beijing, China. 3. School of Public Health, Capital Medical University, Beijing, China. 4. Beijing YouAn Hospital, Capital Medical University, Beijing, China. 5. Sinovac Biotech Co, Ltd, Beijing, China. 6. Xicheng District Center for Disease Prevention and Control, Beijing, China.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific antiviral treatments or vaccines. There is an urgent need for exploring the neutralizing antibodies from patients with different clinical characteristics. METHODS: A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. Antibodies were determined with a modified cytopathogenic neutralization assay (NA) based on live severe acute respiratory syndrome coronavirus 2 and enzyme-linked immunosorbent assay (ELISA). The dynamics of neutralizing antibody levels at different time points with different clinical characteristics were analyzed. RESULTS: The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till days 41-53. The total geometric mean titer was 1:163.7 (95% confidence interval [CI], 128.5-208.6) by NA and 1:12 441.7 (95% CI, 9754.5-15 869.2) by ELISA. The antibody level by NA and ELISA peaked on days 31-40 since onset, and then decreased slightly. In multivariate generalized estimating equation analysis, patients aged 31-45, 46-60, and 61-84 years had a higher neutralizing antibody level than those aged 16-30 years (β = 1.0470, P = .0125; β = 1.0613, P = .0307; β = 1.3713, P = .0020). Patients with a worse clinical classification had a higher neutralizing antibody titer (β = 0.4639, P = .0227). CONCLUSIONS: The neutralizing antibodies were detected even at the early stage of disease, and a significant response was shown in convalescent patients.
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific antiviral treatments or vaccines. There is an urgent need for exploring the neutralizing antibodies from patients with different clinical characteristics. METHODS: A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. Antibodies were determined with a modified cytopathogenic neutralization assay (NA) based on live severe acute respiratory syndrome coronavirus 2 and enzyme-linked immunosorbent assay (ELISA). The dynamics of neutralizing antibody levels at different time points with different clinical characteristics were analyzed. RESULTS: The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till days 41-53. The total geometric mean titer was 1:163.7 (95% confidence interval [CI], 128.5-208.6) by NA and 1:12 441.7 (95% CI, 9754.5-15 869.2) by ELISA. The antibody level by NA and ELISA peaked on days 31-40 since onset, and then decreased slightly. In multivariate generalized estimating equation analysis, patients aged 31-45, 46-60, and 61-84 years had a higher neutralizing antibody level than those aged 16-30 years (β = 1.0470, P = .0125; β = 1.0613, P = .0307; β = 1.3713, P = .0020). Patients with a worse clinical classification had a higher neutralizing antibody titer (β = 0.4639, P = .0227). CONCLUSIONS: The neutralizing antibodies were detected even at the early stage of disease, and a significant response was shown in convalescent patients.
Authors: Thomas J Gniadek; Joshua M Thiede; William E Matchett; Abigail R Gress; Kathryn A Pape; Jessica K Fiege; Marc K Jenkins; Vineet D Menachery; Ryan A Langlois; Tyler D Bold Journal: Transfusion Date: 2020-10-02 Impact factor: 3.157
Authors: Stefania Dispinseri; Massimiliano Secchi; Maria Franca Pirillo; Monica Tolazzi; Martina Borghi; Cristina Brigatti; Maria Laura De Angelis; Marco Baratella; Elena Bazzigaluppi; Giulietta Venturi; Francesca Sironi; Andrea Canitano; Ilaria Marzinotto; Cristina Tresoldi; Fabio Ciceri; Lorenzo Piemonti; Donatella Negri; Andrea Cara; Vito Lampasona; Gabriella Scarlatti Journal: Nat Commun Date: 2021-05-11 Impact factor: 14.919
Authors: Sabra L Klein; Andrew Pekosz; Han-Sol Park; Rebecca L Ursin; Janna R Shapiro; Sarah E Benner; Kirsten Littlefield; Swetha Kumar; Harnish Mukesh Naik; Michael J Betenbaugh; Ruchee Shrestha; Annie A Wu; Robert M Hughes; Imani Burgess; Patricio Caturegli; Oliver Laeyendecker; Thomas C Quinn; David Sullivan; Shmuel Shoham; Andrew D Redd; Evan M Bloch; Arturo Casadevall; Aaron Ar Tobian Journal: J Clin Invest Date: 2020-11-02 Impact factor: 14.808
Authors: Om Prakash; Bhavin Solanki; Jay Sheth; Divyang Oza; Mina Kadam; Sheetal Vyas; Aparajita Shukla; Jayshri Pethani; Hemant Tiwari Journal: J Family Med Prim Care Date: 2021-07-02